The training section of the T32 addiction training program embraces the full spectrum of addiction research. The four-level training section involves pre-doctoral candidates, post-doctoral fellows, rising second-year medical students and psychiatric residents. Program training areas include:
Molecular target development for medications for drug independence – This T0 translational research area emphasizes the application of pharmaceutical sciences to the early phase development of molecular targets for pipeline medications for drug dependence;
Pre-clinical basic science related to emerging drugs of abuse and the development of novel therapies for drug dependence – This T1 translational research area focuses on the application of molecular and animal behavioral models to both characterize the pharmacological mechanisms of emerging drugs of abuse and guide the development of novel antibody and vaccine approaches for the treatment of drug dependence;
Patient-oriented clinical research related to the human neuroscience of the addiction process and controlled clinical trials for the development of novel medications for drug addiction – This T2 translational research area focuses on the application of human brain imaging technologies, controlled clinical trial methodology and longitudinal offspring studies to define a) the neural representations of the development of addiction and its chronically relapsing nature; b) the safety and efficacy of candidate medications to prevent relapse in drug-dependent individuals, and c) the development of outcomes associated with perinatal exposure to drugs of abuse;
Comparative effectiveness and implementation science research for addiction therapies – These T3 and T4 translational research areas deal with the assessment of generalizable clinical effectiveness in “real world settings” and the adoption and incorporation of effective interventions into routine clinical care systems.
Third-year Residents: Martin Watts